AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00106145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0752, Notch Inhibitor - 1 day on, 6 off
Description: Dose escalating in a repeating intermittent dosing schedule of 1 day on/6 days off at rising dose levels of 600, 900, 1200, 1500, 1800, 2400, 3200 mg/day once weekly and then increase at 33% increments.
Study NCT00106145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0752, Notch Inhibitor - 3 days on, 4 off 350 mg
Description: Dose 350 mg capsules daily intermittent 3 days on/4 days off dosing. THIS DOSING SCHEDULE IS NO LONGER UNDER INVESTIGATION
Study NCT03291587 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personnel Training and Coaching Calls
Description: Training of Lung Cancer Screening Personnel on implementation of the US PHS Guidelines for Smoking Cessation and Performance Coaching during Implementation Phase of the Study~Each site will have a coaching team: two members of our research team including an expert in tobacco cessation and an expert in lung cancer screening. Active coaching includes six, 1-1 ½ hour video exchanges among program sites and coaching teams, once every 4-6 weeks over an 8-month implementation phase. One week prior to the call, each site will be prompted with an email to inform the coaching team of any challenges associated with implementation.
Study NCT04705831 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ruconest
Description: C1 Esterase Inhibitor
Study NCT04705831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ruconest
Description: C1 Esterase Inhibitor
Study NCT04135274 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neutrophil to lymphocyte ratio
Description: Neutrophil to lymphocyte ratio
Study NCT03453437 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Self-Compassion
Description: Mindful self-compassion is a course developed by Kristin Neff and Christopher Germer designed to cultivate self-compassion as measured by three subcategories: self-kindness, mindfulness, and a sense of common humanity. This study will shorten the original 8-week course to 5 sessions, and will include interventions and lectures aimed directly toward addressing evaluative concerns perfectionism.
Study NCT02041520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omega 3 fatty acids
Description: omega 3 fatty acids will be administered until progression or unacceptable toxicity develops during 6 months follow up.
Study NCT02041520 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: olive oil in similar presentation of omega 3 fatty acids will be administered until progression or unacceptable toxicity develops during 6 months follow up.
Study NCT02027220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: G-CSF Intracutaneous injection (IC) on days 0, 1, 7, 8, 14, 15, 21 and 22, every four weeks.
Study NCT02027220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib Intravenous injection (IV) on days 1, 8, 15 and 22, every four weeks.
Study NCT02234167 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Risk behaviour and infectious diseases
Description: through counselling, testing vaccination
Study NCT02027220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide, Continuously Intravenous injection (CIV) on days 1, 8, 15 and 22, every four weeks.
Study NCT02027220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone Intravenous injection (IV) on days 1, 2, 8, 9, 15, 16, 22 and 23, every four weeks.
Study NCT00190411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celiprolol
Description: celiprolol
Study NCT00190411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control
Description: Untreated controls excluding betablockers
Study NCT03054402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1834845
Description: Escalating doses of BAY1834845 including comparison of solution and tablet in one dose group
Study NCT03054402 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of placebo
Study NCT03849001 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Conditions
Description: Light Exercise
Study NCT03849001 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Conditions
Description: Moderate Exercise
Study NCT03849001 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Conditions
Description: Vigorous Exercise
Study NCT03849001 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Conditions
Description: Seated Rest
Study NCT02143557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fat-Modified Breast Milk
Study NCT02143557 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MCT formula
Study NCT01013597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Description: LBH589 20mg by mouth three times weekly (Monday/Wednesday/Friday) for 28-day cycles.
Study NCT00862628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebamipide
Description: 100mg tid, 4 or 8 weeks
Study NCT01414985 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAVrh.10CUCLN2
Description: There will be 2 dose cohorts in this study. Group A consists of 2 subjects who have received 9.0x10\^11 genome copies (900,000,000,000 molecules) of the study drug, AAVrh.10CUCLN2. Group B will consist of 6 subjects who will receive a lower dose of 2.85x10\^11 genome copies (285,000,000,000 molecules) of the study drug, AAVrh.10CUCLN2.
Study NCT01531647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: 100 mg q12h Days 8-21
Study NCT01531647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: raltegravir
Description: 400 mg q12h Days 1-4 and 18-21
Study NCT01531647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir
Description: 400 mg q12h Days 1-4 and 18-21
Study NCT01531647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: 100 mg q12h Days 8-21
Study NCT03271203 — intervention group
Intervention type: OTHER
Intervention: Michigan Hand Outcomes Questionnaire
Description: The MHQ is a self-report measure that assesses the function of the hand(s) and/or wrist(s). The MHQ contains six distinct scales including overall hand function, activities of daily living, pain, work performance, aesthetics and subject satisfaction with hand function. In the pain scale, high scores indicate greater pain, while in the other five scales, high scores denote better hand performance.
Study NCT03271203 — intervention group
Intervention type: OTHER
Intervention: Real-time data capture app
Description: Real time data capture app is a smart-phone or web-based application which will allow the subjects to provide responses about their experience of HOA in real-time via varying video, audio, photographic and text forms.
Study NCT02574754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin
Description: warfarin 10 mg PO x 1
Study NCT01783041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-carnitine
Description: Infants will receive L-carnitine 50 micromoles/kg/day, divided into three doses, intravenously for a minimum of 2 weeks or until they achieve enteral feeding volume of 100 cc/kg/day. If infant is receiving 100 cc/kg/day of enteral feeds before the supplementation endpoint, an equivalent dose of enteral L-carnitine will be given to the study patients.
Study NCT01783041 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% Dextrose
Description: Infants will receive 5% dextrose (placebo) three times a day (volume equivalent to the experimental drug) intravenously for a minimum of 2 weeks or until they achieve enteral feeding volume of 100 cc/kg/day. If infant is receiving 100 cc/kg/day of enteral feeds before the supplementation endpoint, an equivalent volume of enteral placebo (5% Dextrose) will be given to the study patients.
Study NCT03722147 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK105
Description: AK105 200 mg intravenously (IV) every-2-weeks (Q2W)
Study NCT04694404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1,Oxaliplatin
Description: Oxaliplatin 85 mg/m2 (D1, q2w) and S-1 (40mg BID for body surface area \< 1.25 m2; 50mg BID for body surface area of 1.25-1.5 m2; and 60mg BID for body surface area >1.5 m2; D1-10, q2w)
Study NCT01871753 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anti-Infective Agents
Description: 10 days of antibiotics, started and selected according to the antibiogram results. In case of reinfection or relapse, re-administration of antimicrobial agents will be performed according to the antibiogram results (for a maximum of 3 cycles of ten days of antibiotics during the 12 months of the follow-up)
Study NCT00753272 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Bio's influenza vaccine GSK2186877A
Description: IM administration, two times one annual dose, 3 different lots will be tested
Study NCT00753272 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix TM
Description: IM administration, two times one annual dose
Study NCT02583139 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Designed Music Narratives
Description: Four music narratives for children each comprising an introductory relaxation exercise, a resource-oriented narrative including guided imagery suggestions and relaxing nature scenarios plus especially composed music.~The narrative and music reflect and support each other.
Study NCT01966471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: Trastuzumab emtansine IV infusion (duration 90 minutes) will be administered at 3.6 mg/kg q3w for up to 18 cycles (1 cycle = 21 days).
Study NCT01966471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab IV infusion (duration 90 minutes) will be administered at 8 mg/kg loading dose followed by 6 mg/kg IV q3w for up to 18 cycles (1 cycle = 21 days).
Study NCT01966471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: Pertuzumab infusion (duration 60 minutes) will be administered at 840 mg loading dose followed by 420 mg IV q3w for up to 18 cycles (1 cycle = 21 days).
Study NCT01966471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: IV infusion of paclitaxel 80 mg/m\^2 once weekly may be administered concurrently with trastuzumab in combination with pertuzumab for 12 weeks.
Study NCT01966471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using epirubicin may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
Study NCT01966471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: 3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using epirubicin may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
Study NCT01966471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using doxorubicin may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
Study NCT01966471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using doxorubicin may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
Study NCT01966471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: IV infusion either docetaxel every 3 weeks (q3w) (at 100 milligram per square meter \[mg/m\^2\] for 3 cycles (1 cycle = 21 days); at 75 mg/m2 for 4 cycles; or start at 75 mg/m\^2 in the first cycle and escalate to 100 mg/m\^2 if no dose limiting toxicity occurs, for a total of 3 cycles at minimum) may be administered concurrently with trastuzumab in combination with pertuzumab.
Study NCT01966471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using cyclophosphamide (FEC) may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
Study NCT01966471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using cyclophosphamide (FEC) may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
Study NCT01966471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using 5-fluorouracil, may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
Study NCT01966471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: 3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using 5-fluorouracil, may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
Study NCT02463565 — intervention group
Intervention type: OTHER
Intervention: no intervention
Study NCT00770341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin 4 mg/kg
Description: MK3009 (daptomycin) once daily by intravenous (IV) drip, 4 mg/kg for 7-14 days for skin and soft tissue infections (SSTI)
Study NCT00770341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: vancomycin
Description: vancomycin 1g, twice daily (b.i.d.) by IV drip, for 7-14 days
Study NCT00770341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin 6 mg/kg
Description: MK-3009 (daptomycin) once daily by intravenous drip, 6 mg/kg for 14-42 days for septicemia or right-sided infective endocarditis
Study NCT03336996 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: stem cell transplantation
Description: the motor nerve fiber damaged patient receive a treatment course stem cell transplantation after the hematoma removal.
Study NCT03336996 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BOLD-fMRI drived DTI scanning
Description: All patients should be receive cranial BOLD-fMRI drived DTI scanning scanning separately before the transplant and after the transplant 0, 1, 3, 6 and 12 months.
Study NCT02739360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Idelalisib 150 mg tablet administered orally twice daily
Study NCT00234806 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Health-e-Access
Description: telemedicine intervention
Study NCT00234806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health-e-Access
Description: telemedicine intervention
Study NCT04094792 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Happify Breather App
Description: Subjects in the intervention group will be cued to breathe at 6 breaths per minute and will receive real time heart rate variability biofeedback. As they increase HRV, screen elements will become more visually appealing.
Study NCT03769012 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-Glucan
Description: 95% beta-glucan sourced from whole cell Euglena Gracilis
Study NCT03769012 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: microcrystalline cellulose
Study NCT00960531 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACC-001+ QS21 (3mcg)
Description: ACC-001 3mcg + QS-21 50 mcg Intra-muscular (IM) q 6 mo
Study NCT00960531 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACC-001 (10 mcg) + QS-21
Description: ACC-001 10mcg + QS-21 50 mcg Intra-muscular (IM) q 6 mo
Study NCT00960531 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACC-001+QS-21 (30mcg)
Description: ACC-001 30mcg + QS-21 50 mcg Intra-muscular (IM) q 6 mo
Study NCT02608320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duragesic (Fentanyl Transdermal System [TDS] Small Patches)
Description: Duragesic 12.5 mcg/h (Treatment A) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
Study NCT02608320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: New JNJ-35685-AAA-G016 (Fentanyl TDS -Small Patches)
Description: New JNJ-35685-AAA-G016 12.5 mcg/h (Treatment B) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
Study NCT02608320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aged JNJ-35685-AAA-G016 (Fentanyl TDS Small Patches)
Description: Aged JNJ-35685-AAA-G016 12.5 mcg/h (Treatment C) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
Study NCT02608320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duragesic (Fentanyl TDS Large Patches)
Description: Duragesic 100 mcg/h (Treatment D) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours, applied to the paraspinal region of the back for 72 hours.
Study NCT03416985 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oral B Healthy Clean Manual Toothbrush
Description: Manual Toothbrush
Study NCT03416985 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BURST Sonic Oral Care
Description: Electric sonic toothbrush
Study NCT03416985 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Philipps Sonicare DiamondClean 300 Series
Description: Electric pulsating toothbrush
Study NCT05518097 — intervention group
Intervention type: OTHER
Intervention: Conventional physical therapy program
Description: Patients with knee osteoarthritis underwent a total of 15 sessions of conventional physical therapy program including hotpack, US, TENS, and exercise 5 days a week, for 3 weeks. Hot pack was applied for 10 minutes, ultrasound was applied continuously at 1 MHz, 1.0 W/cm2 for 10 minutes, and TENS was applied for 30 minutes according to the patient's tolerance. The exercise program consisted of an active, active-assisted range of motion and isometric quadriceps strength training.
Study NCT04347122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid (TXA)
Description: Intervention groups will receive TXA 1g TXA IVPB 10 minutes prior to incision and a second dose of 1g IVPB at the time of closure.
Study NCT02376998 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valiant™ endoluminal procedure
Description: Thoracic endovascular aortic repair with Endoluminal stent-graft placement (Valiant™ endoluminal stent-graft systems (Medtronic Inc., Santa Rosa, CA, USA) will be performed as follows:~The diameter of the stent graft will be calculated from the largest diameter of the proximal/distal neck with an oversizing factor of 10-20%. The procedures will be done with local or general anaesthesia in case of unstable pre-operative hemodynamic conditions.~After the procedure will be completed, a digital subtraction angiography and echocardiography with color-flow mapping were performed to verify the correct positioning of the stent and to detect any primary endoleak.
Study NCT03609073 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endomina
Description: Suturing system then cutting the bridge between the diverticulum and the esophagus.
Study NCT00523510 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infant feeding counseling that includes Flash-heat
Description: Intensive infant feeding counseling which includes description and demonstration of the WHO recommended option for HIV-infected mothers to pasteurize their breastmilk. Flash-heat pasteurization will be described and demonstrated to interested mothers. More intensive counseling and support will be provided home visits.
Study NCT02796170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: 5mg pill taken once daily
Study NCT02608320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: New JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches)
Description: New JNJ-35685-AAA-G021 100 mcg/h (Treatment E) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
Study NCT02796170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 5mg pill taken once daily- placebo of Dapagliflozin
Study NCT02608320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aged JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches)
Description: Aged JNJ-35685-AAA-G021 100 mcg/h (Treatment F) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
Study NCT04100642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hemay808
Description: topical apply
Study NCT04100642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay808
Description: topical apply